ArticleESMO real world data and digital oncology2026
First-line osimertinib in advanced
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: First-line osimertinib is standard for advanced Patients and methods: Multicenter retrospective cohort from eastern Spain including patients with advanced Results: Among 268 patients, median age was 72 years, 27.6% had Eastern Cooperative Oncology Group performance status ≥2, and 42.5% had brain metastases. Osimertinib achieved an ORR of 73.5%, rwPFS of 17.5 months, and rwOS of 28.1 months, but only 50.1% of patients who progressed initiated second-line therapy. Among 180 patients with documented progression, 51 (28.3%) had OPD and 82.4% received LAT. Exploratory analyses suggested clinically meaningful improvements in median PFS and median OS versus the overall cohort. Re-biopsy identified resistance mechanisms (e.g. Conclusions: In routine practice, first-line osimertinib shows robust effectiveness but lower rwOS than expected and substantial post-progression attrition. These findings underscore the need for risk-adapted treatment strategies and support prospective evaluation of OPD management approaches, including integration of LAT alongside contemporary systemic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.